Navigation Links
PAREXEL International To Present At Citi Global Healthcare Conference
Date:2/20/2013

BOSTON, Feb. 20, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Citi Global Healthcare Conference in New York.  James Winschel, Sr. Vice President and Chief Financial Officer, will be making a presentation on PAREXEL and discussing business developments at 10:20 a.m.  ET on Wednesday, February 27, 2013.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until May 27, 2013.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 74 locations throughout 51 countries around the world, and has approximately 14,000 employees, including 282 employees related to the acquisition of Liquent. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, Perceptive Informatics is a trademark of Perceptive Informatics, Inc., and Liquent is a registered trademark of Liquent, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc., Liquent, Inc. or their respective owners and are hereby acknowledged.

Contact:

Jill Baker , Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@parexel.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International Reports Second Quarter Fiscal Year 2013 Results
2. PAREXEL International To Present At Oppenheimer Healthcare Conference
3. PAREXEL International To Present At Lazard Capital Healthcare Conference And Jefferies Global Healthcare Conference
4. PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program
5. PAREXEL International to Present at Robert Baird Healthcare Conference
6. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
7. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
8. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
9. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
10. PAREXEL International To Present At NASDAQ OMX Investor Conference
11. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/28/2017)... LONDON , March 28, 2017  "US ... insight on the various indicators and trend analysis ... generics drugs in mainstream pharmaceutical market in US. ... responsible for the growth on cancer generics drugs ... resulted in saving of billions of dollars for ...
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
Breaking Medicine Technology:
(Date:3/28/2017)... NEW YORK (PRWEB) , ... March 28, 2017 ... ... development, NTX Technology™, is the first technology to directly address the resolution to ... Organization. NTX Technology™ is a patented compound of FDA and TTB approved ingredients ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
Breaking Medicine News(10 mins):